64 patents
Page 2 of 4
Utility
Electrode Arrays For Electroporation, and Related Systems and Methods
5 Jan 23
An electrode array for use with an electroporation device includes a support member having a top surface and a bottom surface and defines a plurality of injection channels extending from the top surface to the bottom surface.
Jay McCoy, Paul Fisher, SR.
Filed: 30 Jun 22
Utility
Device and Method for Single-needle In Vivo Electroporation
5 Jan 23
Described is a device and method for administration of molecules to tissue in vivo for various medical applications, the device comprising a single hypodermic injection needle and at least two spaced elongate electrodes which provide for the ability, when the needle is inserted into tissue, such as skin or muscle, to pulse tissue with a non-uniform electric field sufficient to cause reversible poration of cells lying along or in close proximity to the track made by the needle upon its insertion into said tissue.
Rune KJEKEN, Iacob MATHIESEN, Torunn Elisabeth TJELLE, George MCHUGH
Filed: 29 Apr 22
Utility
Vaccines Against Coronavirus and Methods of Use
24 Nov 22
Provided herein are methods of inducing an immune response against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof by administering an immunogenic composition to the subject, wherein the subject exhibits: an increase in antigen-specific cellular immune response as measured by Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) assay relative to baseline; and/or an increase in neutralizing antibody response as measured by a pseudovirus neutralizing assay relative to baseline.
Jian Yan, Kate Broderick, David Weiner, Kar Muthumani, Ami Patel
Filed: 5 May 22
Utility
Immunogenic Compositions Against SARS-COV-2 Variants and Their Methods of Use
27 Oct 22
Disclosed herein are nucleic acid molecules encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a SARS-CoV-2 infection in a subject.
Charles Reed, Stephanie Ramos, Trevor Smith, Maria Yang, Richa Kalia, Kate Broderick
Filed: 22 Apr 22
Utility
Methods of Inducing Immune Response Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern
20 Oct 22
Disclosed herein are methods of administering and uses of a plasmid encoding residues 19-1279 of SEQ ID NO: 1, a plasmid comprising nucleotides 55-3837 of SEQ ID NO: 2, pGX9501, INO-4800 drug product, or a biosimilar thereof to induce an immune response against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) variant B.1.351, SARS-CoV-2 variant B.1.1.7, SARS-CoV-2 variant P.1, SARS-CoV-2 variant B.1.617.1, SARS-CoV-2 variant B.1.617.2, or SARS-CoV-2 variant B.1.1.529.
Trevor Smith, Stephanie Ramos, Viviane Machado De Mello Andrade
Filed: 13 Apr 22
Utility
Cancer Vaccines Targeting LEMD1 and Uses Thereof
25 Aug 22
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus LEMD1 antigen.
Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
Filed: 25 Apr 22
Utility
Cancer Vaccines Targeting PRAME and Uses Thereof
25 Aug 22
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen.
Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
Filed: 25 Apr 22
Utility
Electroporation Device Having a Battery Pack with Power Switch
16 Jun 22
An electroporation device having a battery pack including a plurality of battery cells and at least one lead in electrical communication with a circuit board.
Beat Stadelmann, Stephen Kemmerrer
Filed: 7 Mar 22
Utility
Cancer Vaccines Targeting MUC16 and Uses Thereof
14 Apr 22
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen.
Jian YAN, Anna SLAGER, Bradley GARMAN, Neil COOCH
Filed: 22 Dec 21
Utility
Dna Antibody Constructs for Use Against Middle East Respiratory Syndrome Coronavirus
14 Apr 22
Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-CoV) viral antigen.
David WEINER, Trevor RF SMITH, Kar MUTHUMANI
Filed: 23 Dec 21
Utility
DNA Antibody Constructs And Method Of Using Same
14 Apr 22
Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody.
David Weiner, Karuppiah Muthumani, Seleeke Flingai, Niranjan Sardesai
Filed: 17 Dec 21
Utility
Consensus Prostate Antigens, Nucleic Acid Molecule Encoding The Same And Vaccine And Uses Comprising The Same
20 Jan 22
Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens.
David Weiner, Jian Yan, Bernadette Ferraro, Niranjan Y. Sardesai, Mathura P. Ramanathan
Filed: 28 Jun 21
Utility
Foot and Mouth Disease Virus (FMDV) Consensus Proteins, Coding Sequences Therefor and Vaccines Made Therefrom
13 Jan 22
Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences.
David B. Weiner, Bernadette Ferraro, Jian Yan, Patricia A. Brown, Rodney A. Bowling, Douglas R. Kern, Mathura P. Ramanathan, Niranjan Y. Sardesai, Karuppiah Muthumani
Filed: 14 Sep 21
Utility
Cancer Vaccines Targeting Boris and Uses Thereof
30 Dec 21
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen.
Jian YAN, Anna SLAGER, Bradley GARMAN, Neil COOCH
Filed: 20 Sep 21
Utility
Cancer Vaccines Targeting Mesothelin and Uses Thereof
30 Dec 21
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen.
Jian YAN, Anna SLAGER, Bradley GARMAN, Neil COOCH
Filed: 7 Sep 21
Utility
MERS-CoV Vaccine
30 Dec 21
Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen.
David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai
Filed: 10 Sep 21
Utility
Checkpoint Inhibitor and Vaccine Combinations and Use of Same for Immunotherapy
30 Dec 21
Disclosed herein is a vaccine comprising an antigen and checkpoint inhibitor.
David Weiner, Karuppiah Muthumani, Niranjan Sardesai
Filed: 14 Sep 21
Utility
Filovirus Consensus Antigens, Nucleic Acid Constructs and Vaccines Made Therefrom, and Methods of Using Same
16 Dec 21
Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Ebolavirus glycoproteinimmunogens are disclosed.
David B. Weiner, Ami Patel, Jian Yan
Filed: 17 Aug 21
Utility
Tumor-specific Neoantigens and Methods of Using the Same
25 Nov 21
The disclosure relates to methods of manufacturing individualized vaccines that comprise nucleic acid molecules that encode one or more neoantigens specific for antigens that are expressed by a tumor in a subject.
Elizabeth Kennedy Duperret, Alfredo Perales Puchalt, David Weiner, Niranjan Y. Sardesai
Filed: 28 May 19
Utility
Vaccines For Recurrent Respiratory Papillomatosis And Methods Of Using The Same
18 Nov 21
Provided herein are nucleic acid molecules encoding an HPV antigen.
Stephanie Ramos, Jewell Walters, Jian Yan, Anna Slager, Charles Reed, Kate Broderick
Filed: 14 May 21